BioSpace News Archive

Florida Cancer Specialists & Research Institute, LLC (FCS) physicians are presenting the outcomes of 23 clinical trials, the majority being Phase 1, at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting on June 2 – 6 in Chicago, Illinois.

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on June 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 3 individuals hired by Acutus in May 2023.

Replimune Group, Inc. announced that members from the Replimune management team will present in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023 at 1:00 PM ET at the Marriot Marquis in New York NY.

Miromatrix Medical Inc. announced that Miromatrix and John Barry have mutually agreed to end his employment as Vice President of Research and Development effective on or around June 13, 2023, and that Jeff Ross, Ph.D., Chief Executive Officer, will assume leadership responsibilities for the R&D organization.

Oncorus, Inc. announced that, in response to challenges associated with raising additional capital and pursuing strategic alternatives to secure additional funding, including current market conditions, the Company’s board of directors has approved a workforce reduction of approximately 55 employees, representing substantially all of Oncorus’ workforce, which is expected to be completed by August 2023.

TScan Therapeutics, Inc. announced the closing of an underwritten public offering of 23,287,134 shares of its voting common stock, at a public offering price of $2.00 per share, and pre-funded warrants to purchase up to an aggregate of 47,010,526 shares of its voting common stock at a price to the public of $1.9999 per pre-funded warrant, which represents the per share public offering price for the voting common stock less the $0.0001 per share exercise price for each such pre-funded warrant.

BostonGene today announced that four abstracts have been accepted for poster presentations and two abstracts have been accepted for online publication for the 2023 ASCO Annual Meeting (ASCO), which will be held June 2 – 6, 2023, at McCormick Place Convention Center in Chicago, IL.

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced that it is scheduled to speak at the William Blair 43rd Annual Growth Stock Conference.

Compass Therapeutics, Inc. announced that the Company will participate in the following investor events during the month of June 2023.

GenEros Biopharma Ltd. (“GenEros” or “the Company”) will unveil the preliminary data from the phase I clinical trial of GEC255, a unique KRAS G12C inhibitor, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.